Clearmind Medicine Engages Experienced CRO to Support its First-in-Human Clinical Trial
Clearmind Medicine Inc. recently announced additional preparations to facilitate the commencement of the company’s clinical trial and engaged a contract research organization (CRO) to provide support for the company.
The CRO will act as a project manager, provide support in regulatory affairs, site selection and initiation, recruitment support, clinical monitoring, data management, and more.
The company’s upcoming first-in-human clinical trial will evaluate the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD). CMND-100 is Clearmind’s novel psychedelic-derived drug, based on its proprietary MEAI molecule.
“We are thrilled to continue moving forwards towards our first-in-human clinical trial,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. “We are entering an advanced stage according to timelines, bringing us closer to being able to treat alcoholism, a common problem that affects both young people and adults.”
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The company’s intellectual portfolio currently consists of fourteen patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol CMND and the Frankfurt Stock Exchange under the symbol CWY. For more information, visit https://www.clearmindmedicine.com.
Total Page Views: 1998
